Instruction for use: Segan

Dosage form: tablets

Active substance: Selegiline*

ATX

N04BD01 Selegiline

Pharmacological groups:

Dopaminomimetics

Anti-Parkinsonics

The nosological classification (ICD-10)

F00 Dementia in Alzheimer's Disease (G30 +): Alzheimer's dementia; Alzheimer's dementia; Dementia in Alzheimer's disease

G20 Parkinson's disease: A trembling paralysis; Idiopathic Parkinsonism; Parkinson's disease; Symptomatic Parkinsonism

Composition and release form

1 tablet contains selegiline hydrochloride 5 mg; In a contour acheive box 20 pcs., In a cardboard bundle 3 packs.

Pharmachologic effect

Mode of action - antiparkinsonian.

Inhibits MAO type B, increases the content of dopamine and catecholamines in the brain, incl. In the extrapyramidal system.

Pharmacokinetics

Quickly absorbed from the digestive tract. Cmax -. 2,2 ± 0,9 ng / ml achieved after 0.5-2 hours of selegiline and its metabolites well pass through the BBB, the tissues and body fluids. Metabolized by the cytochrome P450 system. The main metabolites are L-methamphenamine, L-amphenamine and N-demethylselegiline. T1 / 2 -. 26 ± 11 hours is displayed in the urine as L-metamfenamina (20-63%), L-amfenamina (9-26%), N-demetilselegilina (1%) and the feces (15% for 72 H).

Indication of the preparation Segan

Parkinson's disease (mono- or combination therapy), dementia of the Alzheimer's type (complex therapy).

Contraindications

Hypersensitivity, extrapyramidal disorder, psychosis, hypertension, severe angina pectoris, arrhythmias, endocrine disorders (pheochromocytoma, diffuse toxic goiter), angle-closure glaucoma, peptic ulcer and duodenal ulcer, prostate adenoma, dementia, dermatitis of unknown aetiology, concomitant use of antidepressants and Period up to 5 weeks after their cancellation, pregnancy, breast-feeding.

Application in pregnancy and breastfeeding

Contraindicated. At the time of treatment should stop breastfeeding.

Side effects

From the nervous system and sensory organs: headache, dizziness, drowsiness / insomnia, anxiety, hallucinations, confusion, psychosis, dyskinesia / bradykinesia, memory impairment, disorientation, depression, decreased libido, ringing in the ears, blurred vision.

From the cardiovascular system and blood (hematopoiesis, hemostasis): palpitation, orthostatic hypotension, arrhythmia.

On the part of the intestine: anorexia, dry mouth, nausea, constipation / diarrhea.

Other: weight loss, urinary retention, sexual dysfunction, rash, dyspnea, increased level of hepatic transaminases.

Interaction

Strengthens and lengthens the effect of levodopa, amantadine, anticholinergics, catecholamines, alcohol. Tricyclic antidepressants potentiate side effects.

Dosing and Administration

Inside, with meals, with monotherapy: 5 mg 2 times a day; in combination therapy with levodopa starting dose - 5.10 mg of 1 or 2 times per day (morning and afternoon), then after 2-3 days of levodopa dose is reduced by 10-30%.

Overdose

Symptoms: dizziness, headache, agitation, seizures, cardiac arrhythmias, hypertension, hyperthermia, excessive sweating, respiratory depression.

Treatment: induction of vomiting, gastric lavage, the use of activated charcoal; With excitation and convulsions IV the introduction of diazepam; Symptomatic therapy.

Precautionary measures

If the liver or kidney function is impaired, lower doses are necessary. Do not use during work drivers of vehicles and people whose profession is associated with increased concentration of attention. It should be refrained from the use of the drug in pediatric practice (safety and efficacy not determined).

Storage conditions of the drug Segan

In dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life of the drug Segan

3 years.

Do not use after the expiry date printed on the package.